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PILOT RANDOMIZED TRIAL OF A CROSS-DIAGNOSIS
COLLABORATIVE CARE PROGRAM FOR PATIENTS
WITH MOOD DISORDERS
Amy M. Kilbourne, Ph.D., M.P.H.,1,2∗ Decartes Li, M.D.,3 Zongshan Lai, M.S.,1,2
Jeanette Waxmonsky, Ph.D.,4 and Terrence Ketter, M.D.5
Objectives: Chronic care models improved outcomes for persons with mental
disorders but to date have primarily been tested for single diagnoses (e.g. unipolar
depression). We report findings from a pilot multisite randomized controlled
trial of a cross-diagnosis care model for patients with mood disorders. Methods:
Patients (N = 60) seen in one of four primary care or mental health clinics
affiliated with the National Network of Depression Centers were randomized
to receive a mood disorder care model, Life Goals Collaborative Care (LGCC,
N = 29) or usual care (N = 31). LGCC consisted of five group self-management
sessions focused on mood symptom coping and health behavior change strategies
followed by monthly patient and provider care management contacts for up to
6 months. Outcomes at 3 and 6 months included mood symptoms (Patient Health
Questionnaire—PHQ-9, Internal State Scale—well-being, Generalized Anxiety
Disorder scale) and health-related quality of life. Results: Of the 60 enrolled,
the mean age was 46.2 (SD = 13.2), 73.3% were female, 16.7% were non-
white, and 36.8% had a bipolar disorder diagnosis. LGCC was associated with
greater likelihood of depressive symptom remission in 6 months (respectively,
50% versus 19% had a PHQ-9 score ≤9 and 50% reduction in PHQ-9 score,
P = .04) and improved well-being (β = 2.66, P ≤ .01, Cohen’s D = 0.43).
Conclusions: LGCC may improve outcomes for patients regardless of mood
diagnosis, potentially providing a feasible and generalizable chronic care model
for routine practice settings. Depression and Anxiety 30:116–122, 2013. C©
2012 Wiley Periodicals, Inc.
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INTRODUCTION
Chronic mood disorders (bipolar disorder and
recurrent unipolar major depressive disorder) are the
leading causes of disability worldwide.[1, 2] When left
untreated, they can lead to premature mortality, par-
ticularly from suicide.[1] A recent report by the U.S. In-
stitute of Medicine (IOM) and others documented sub-
stantial gaps in evidence-based care for mental disorders,
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citing poor quality in detection, treatment, and follow-
up care.[2] Although unipolar depression is more com-
mon, bipolar disorder is more costly on a per patient
basis due to its chronic and severe nature.[3]
Collaborative chronic care models[4, 5] have demon-
strated efficacy and cost-effectiveness in managing
unipolar major depressive disorder,[6–10] and more re-
cently, bipolar disorder.[11–14] These care models involve
a care manager who provides patient self-management
education, coordinated care between primary care and
mental health providers, and systematic dissemination of
information related to treatment guidelines. Care mod-
els have been found to be cost neutral for bipolar disor-
der, and in depression, cost-effective compared to usual
care, suggesting that care models may ultimately prove
financially feasible not only in the public but also in the
private sector.[6]
However, to date, most care models for mental disor-
ders have been implemented for a single diagnosis such
as depression.[6] There is growing demand for cross-
diagnosis care models, in order to maximize their reach
and to make them more appealing to providers, who
might be reluctant to hire multiple care managers for
different mental health diagnoses. Combining diagnos-
tic groups also has the potential to decrease waiting time
for patients to participate in clinical interventions. Mood
disorders serve as an ideal starting point in which to im-
plement a cross-diagnosis care model, notably because
they are common, with U.S. population prevalence rates
estimated at 16% for unipolar depression[15] and 4%
for bipolar spectrum disorders.[16, 17] The goal of this
pilot randomized controlled trial was to implement a
cross-diagnosis care model for patients with mood dis-
orders across a national sample of clinics and deter-
mine whether, compared to patients receiving usual care,
those randomized to receive LGCC had improved out-
comes, notably decreased mood disorder symptoms over
a 6-month period.
MATERIALS AND METHODS
This single blind multisite randomized controlled trial compared
patients receiving LGCC to those receiving usual care across four sites
affiliated with the National Network of Depression Centers (NNDC)
at the University of Colorado, University of Michigan, University of
California, San Francisco, and Stanford University. One of the sites
(Michigan) was a primary care practice whereas the others were men-
tal health specialty programs. Clinics participating in the pilot study
identified a mental health clinician “champion” who served as the pri-
mary point of contact to help identify potentially eligible patients,
and also designated an existing provider to implement LGCC at their
clinic. LGCC care managers were existing providers, three of which
were master’s level clinical social workers and one was a PhD-level
psychologist. This study was reviewed and approved by local Institu-
tional Review Boards of the participating institutions, and all patients
provided verbal and written informed consent prior to participation.
Patients were eligible if they had a current diagnosis of unipolar
major depressive disorder or bipolar disorder (Type I, II, or Not Oth-
erwise Specified), based on screening by the designated clinician, using
checklists of mood disorder criteria derived from the text revision of
the fourth edition of the Diagnostic and Statistical Manual of Men-
tal Disorders (DSM-IV-TR, American Psychiatric Association, 2000).
Exclusion criteria were minimal in order recruit a real-world clini-
cal outpatient mood disorder sample, and included at the time of en-
rollment having acute alcohol/substance use, psychiatric, or medical
disorders that required inpatient treatment, active alcohol/substance
intoxication, acute medical illness, dementia, or active suicidal ideation.
The clinicians at each site screened patients and eligible patients were
asked if they wanted to be part of the study. Patients agreeing to par-
ticipate provided informed consent and completed an assessment that
included questions on symptoms, quality of life, and other clinical and
demographic features used in prior studies.[13,14]
INTERVENTION
After agreeing to participate, patients were randomized to re-
ceive LGCC or usual care. Life Goals Collaborative Care (LGCC)
is based on the care model for bipolar disorder[13,14] expanded to
address unipolar depression as well. Those randomized to LGCC
were first contacted by the Care Manager who then scheduled in-
tervention sessions. LGCC involved five group self-management ses-
sions that included those diagnosed with either unipolar depression
or bipolar disorder, followed by monthly care management contacts
with both patients and providers for up to 6 months. LGCC self-
management sessions were based on the Life Goals program, described
previously,[13,14] and were expanded to include anxiety as well as de-
pressive and manic symptom coping strategies. Sessions lasted approx-
imately 90–120 min each and were semidirective, in which the Care
Manager used motivational enhancement and elicited active discus-
sions regarding management of mood symptoms. In particular, ses-
sions covered mood disorder basics and issues around stigma (session
1), personal mood symptom profiles, coping strategies, and healthy
behaviors to mitigate mood symptoms (sessions 2–4), and preparing
an action plan for mood symptom coping and navigating healthcare
appointments (session 5).
LGCC care management consisted of provider support through
brief (15–20 min) follow-up phone contacts to the patient and provider
by the care manager. During this period, care managers coordinated
care with patients’ primary care and/or mental health physicians, in
particular, cueing providers if there was deterioration or no clini-
cal or functional improvement and providing additional information
on bipolar disorder and unipolar depression treatment guidelines if
warranted (e.g. bipolar depression, hypomanic symptoms). Additional
provider support for evidence-based decision making included the use
of an electronic registry by the Care Manager to track symptoms and
progress in which summary information on patient status was relayed
back to the physician by the Care Manager.
LGCC Care Managers were trained by study investigators that in-
cluded didactic instruction on management of depression and bipolar
disorder along with hands-on training in the LGCC self-management,
care management, and registry implementation. Additional training
was provided on topics such as the boundary between depression and
bipolar II disorder/bipolar disorder not otherwise specified (e.g. how
to assess and treat with input from treating psychiatrists) and strategies
for managing treatment-refractory depressive symptoms.
Usual care across the four sites was consistent in that it included
guideline-informed standard mental health treatment by psychiatrists
in the respective clinics (at the University of Michigan, a psychiatrist
was co-located at the primary care clinic) but none of the LGCC com-
ponents. No other psychosocial programs were offered to the patients
during the intervention period.
MEASURES
Patients self-completed brief assessments at baseline, 3 months and
6 months. LGCC was designed to reduce mood symptom burden and
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improve health-related quality of life based on previous trials.[13,14]
The primary outcome was depressive symptoms based on the 9-item
Patient Health Questionnaire (PHQ-9), a widely used and previously
validated assessment of depressive symptoms.[18] Secondary outcomes
included the Quick Inventory of Depressive Symptomatology (QIDS),
and 16-item assessment of depressive symptoms,[19] and the Internal
State Scale (ISS),[20] an 8-item assessment of manic symptoms and
overall well-being that has been strongly correlated clinician ratings
of mood disorders and improved quality of life. In addition, anxiety
symptoms were assessed based on the Generalized Anxiety Disorder
scale (GAD-7),[21] and health-related quality of life was assessed using
the short-form 12-item survey (SF-12) in which mental and physical
health component scores were generated.[22]
We also assessed potential mediators across the LGCC and UC
groups, notably medication adherence and completion of LGCC ses-
sions/contacts. The brief assessment also included a self-completed
question on mood disorder medication adherence, based on previously
established assessments. Self-reported “good” adherence was defined
as response to a question on number of days in which he or she missed
any of their antidepressant or mood stabilizer doses in the past 4 days
(0, 1, 2, 3, or 4 days). A cutpoint of 0 days was categorized as adher-
ent whereas any missed days was defined as nonadherent This defini-
tion (i.e. perfect self-reported adherence) was strongly associated with
good adherence based on electronic cap monitoring (≥80% correct
cap openings) in a primary care patient population.[23]
ANALYSES
Statistical analyses (intent-to-treat) ascertaining the effect of LGCC
were considered exploratory, as this was a pilot study. Thus, a signif-
icance threshold of P < .05 was used and a correction for multiple
comparisons was not applied. Repeated measures analyses were used
to determine the effect of LGCC versus usual care on outcomes, ad-
justing for the baseline value of the outcome, effect of the LGCC, time
(3, 6 months), medication adherence, and the interaction of time and
LGCC effect. Effect sizes were estimated using Cohen’s D. In addi-
tion, using logistic regression analyses, we compared the probability
of remission from depression based on PHQ-9 scores. Depression re-
mission was defined based on two definitions: (1) 50% reduction in
PHQ-9 score and 6-month PHQ-9 score of 9 or lower, or (2) PHQ-
9 score of 4 or lower (≤5) using established definitions for clinical
significance.[18] Finally, sensitivity analyses were conducted in which
we stratified repeated measures analyses by mood disorder diagnosis
(bipolar disorder, unipolar depression) to assess whether LGCC had a
differential effect on these patients.
RESULTS
Out of 92 eligible patients approached, 32 declined
to participate, leaving 60 for this pilot study. Of the 60
enrolled, 29 were randomized to LGCC and 31 to usual
care, and all 60 completed baseline and 6-month follow-
up assessments. Overall, the mean age was 46.2 (SD =
13.2), 73.3% were female, 16.7% were non-white, and
36.8% had a bipolar disorder (type I or II) diagnosis.
There were no significant differences in demographic
characteristics among those who declined versus those
who were enrolled or in those assigned to LGCC versus
treatment as usual. Among those randomized to LGCC,
the mean (±SD) number of group sessions and follow-up
care management contacts were, respectively, 4.0 (±1.7)
and 4.1 (±4.0).
Repeated measures analyses (Table 1) found that
the effect of LGCC on reductions in depressive symp-
toms as measured by changes in PHQ-9 scores ap-
proached significance (β = −1.56, P = .09; Cohen’s
D = 0.18). However, patients randomized to LGCC
versus usual care were significantly more likely to have
a 50% reduction in PHQ-9 score and a PHQ-9 score
of ≤9 at 6 months (respectively, 50.0% versus 19.1%,
OR = 9.4, P = .04) based on logistic regression analyses
(Table 1). In addition, 36.8% of those enrolled in LGCC
achieved a PHQ-9 score of ≤5 compared to 19.1% in
the usual care group, but this finding was not statistically
significant.
LGCC compared to usual care was also associated
with improved well-being (β = 2.66 P ≤ .01, Cohen’s
D = 0.43) based on repeated measures analysis
(Table 1). These changes appeared to not be attributable
to changes in medication adherence: as similar rates of no
missed doses were evident for the LGCC and usual care
groups at 6 months: respectively, 81.3% versus 80.0%,
OR = 1.1, P = .92.
Repeated measures analyses stratified by diagnosis
(bipolar disorder or unipolar depression) revealed simi-
lar trends and larger effects for patients diagnosed with
bipolar disorder (Table 2). Among patients diagnosed
with unipolar depression, those receiving LGCC re-
ported improved well-being in 6 months compared to
those in the UC group.
DISCUSSION
To our knowledge this was the first study of a cross-
diagnosis mood disorder care model implemented across
different treatment settings (primary care, specialty men-
tal health) by existing providers. The evidence support-
ing the efficacy/effectiveness of cross-diagnosis cronic
care models (CCMs) mental health programs,[25] and
depression and co-occurring medical conditions,[26] en-
hancing the generalizability and overall value of the
CCM for mental disorders in routine practice.
This was also the first dissemination of a collabora-
tive care model-based intervention across the NNDC,
the largest network of its kind focused on research and
treatment related to depression and bipolar disorders.
CCMs typically include patient self-management edu-
cation, coordination of follow-up care by a nonphysician
provider, and ongoing symptom monitoring and popu-
lation management for people with chronic medical or
mental health diagnoses. This study provides a template
for research and clinical care involving a single network
entity, services; ultimately simplifying training and re-
ducing cost and complexity.
We found that LGCC compared to usual care out-
comes, notably improved depression remission and over-
all well-being. Previous trials of care models applied
to bipolar disorder had a less effect on depressive
than manic symptoms.[11, 12] We found that half of pa-
tients randomized to LGCC achieved a 50% reduc-
tion in PHQ-9 score and a 6-month score of ≤9. The
Depression and Anxiety




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Research Article: Mood Disorders Care Model 121
observed clinically significant reduction in well-being
also shows that the care model may potentially benefit
those with a wider range of persons with mood disorders.
Well-being in particular is associated with improved
functioning overall and is a potentially generalizable
marker for improved outcomes across mental health
diagnoses.[2]
In contrast to previous studies, LGCC was not associ-
ated with improved health-related quality of life.[11, 12]
Prior studies found significant differences in mental
health physical health-related quality of life,[11, 12] af-
ter a follow-up period of at least 2 years. Nonetheless,
improvements in mood symptoms, particularly depres-
sion and well-being, has been shown to be associated
with clinically significant changes in outcomes including
health-related quality of life, functioning, and survival in
previous studies of the care model.[6]
Limitations of the study included a small sample size,
which limited statistical power to detect mood bene-
fits, and a relatively short follow-up period, which may
have limited our ability to observe potential changes in
longer-term outcomes such as quality of life observed in
earlier LGCC trials.[10, 12] This pilot study also lacked
sufficient statistical power to also explore mechanisms
of treatment effect, such as bipolar disorder diagnosis or
potential diagnosis switching.
Overall, our study provided preliminary evidence that
cross-diagnosis care model was feasible to implement
and could improve outcomes among diverse mood dis-
order patients seen in different treatment settings. Our
findings suggest that further cross-diagnosis care model
research is warranted, including assessments of dissem-
ination of care models across an even wide range of di-
agnosis (e.g. mood, anxiety disorders) and exploration
of the feasibility of reimbursement models in the pri-
vate sector, as well as the application of technologies
such as telemedicine or web-based applications to facili-
tate the uptake of LGCC and other care models in rou-
tine practice.[27] In addition, the potential effectiveness
of collaborative care models such as LGCC has impli-
cations for healthcare reform, notably in the implemen-
tation of Accountable Care Organizations (ACOs).[28]
Given the substantial prevalence of mood disorders in
general medical care settings, integrated mental health-
care models within ACOs are needed. ACOs have po-
tential to improve care for mood disorders through in-
centives for better performance and bundled payments
that can support care managers who can implement
key components of care models (e.g. self-management
sessions, measurement-based care). Ultimately, manual-
based, cross-diagnosis care models such as LGCC that
can be easily adopted by existing providers have the po-
tential to improve efficiency, quality, and outcomes for
this vulnerable group across different care settings.[29, 30]
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